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Presence of cerebral microbleeds on MRI:
what are the therapeutic implications?
Cerebral microbleeds (CMB) on gradient-recalled
echo (GRE) T2-weighted MRI are considered a biomarker
for micrangiopathy or bleeding-prone small-vessel diseases.
Identifying high-risk patients before treatment with
antiplatelet or antithrombotic agents could potentially reduce
the hazard of Intracerebral Haemorrhage (ICH). 
What do we know about the association
between the use of antithrombotics or
anticoagulation, ICH and CMBs?
Gregoire et al investigated the association of CMB
with (ICH) with respect to use of antiplatelet agent. They
found that CMBs were more frequent, more lobar in location
and were more numerous in antiplatelet- users with ICH than
in antiplatelet users without lobar ICH. The number of CMBs
was associated with the risk of antiplatelet-related ICH with
(adjusted OR 1.33 per additional CMB). The authors
concluded that in patients with a large number of lobar
CMBs, the risk of ICH could outweigh the benefits of
antiplatelet therapy. 
Sang et al observed, in 107 patients with primary ICH,
that primary ICH with CMBs was more common in elderly
patients with prominent ischemic change and frequent use of
antithrombotics or anticoagulants. Wong at al analyzed
aspirin use with and without ICH and its association with
presence of CMBs with 21 patients in each group. The
authors observed that both the presence and the number of
CMBs were more common in aspirin-users with ICH. Fan et
al studied prospectively a Chinese cohort of 121 acute
ischaemic stroke patients for stroke recurrence and ICH in
association with CMBs. Of the 43 (35%) patients having
CMBs, 16 developed recurrent stroke. No difference in the 11
patients with ischaemic stroke was seen in association with
presence of CMBs. Of the 5 patients who had ICH, 4 patients
had CMBs. 
In a cohort of 106 Japanese patients with ICH, the
prevalence of CMB was found to be 54.7% which was
significantly associated with advanced age, white matter
hyperintensity and previous ICH or ischaemic stroke.
Nonetheless, no association was found between the presence
of CMBs and regular use of antiplatelet agent irrespective of
previous history of stroke.
What is the data on association of thrombolytic
use, ICH and CMBs?
Kidwell investigated the presence of CMBs in
pretreatment MRI of 41 patients undergoing intra-arterial
thrombolytic therapy for acute ischaemic stroke. Five patients
demonstrated CMBs. Only 1 patient had a haemorrhagic
transformation and the symptomatic haemorrhage occurred at
the site of a prior CMB opposite to the site of ischaemia.
Major symptomatic haemorrhage occurred in 1 of 5 patients
with CMBs compared to 4 of 36 patients without CMBs. 
Derex et al conducted a retrospective analysis of pre-
treatment T2-weighted MRI of 44 patients who underwent
thrombolysis (intravenous Alteplase) for acute ischaemic
stroke. CMBs were found on pretreatment MRI in 18.2%
patients. Neither symptomatic nor asymptomatic ICH had
any significant association with CMBs till day 7 of follow-up.
Interestingly, no ICH was seen to occur at the site of CMB
while all patients had ICH within the ischaemic area. 
Kakuda et al prospectively evaluated MRI of 77
patients with acute ischaemic stroke treated with
intravenous Alteplase on day 1 and day 30 (mean age, 71
years; 31 men). CMBs were identified in 15.7% patients.
They also reported that no significant difference was
observed in the frequency of either symptomatic or
asymptomatic haemorrhagic complications after
thrombolysis between patients with and without CMBs at
baseline. None of the patients with CMBs at baseline had a
symptomatic ICH. Therefore, the presence of CMBs on
gradient echo imaging does not appear to substantially
increase the risk of either symptomatic or asymptomatic
brain haemorrhage following intravenous Alteplase.
Conclusion
Current data is insufficient to support the hypothesis that
CMBs are associated with a higher risk of ICH or haemorrhagic
transformation after thrombolytic therapy in patients with
stroke. Larger prospective studies are required to investigate the
predictive value and therapeutic implication of CMBs with
regard to the use of antithrombotic agents, anticoagulation or
thrombolytic therapy and associated risk of ICH; however the
current data suggests caution in the use of these agents for stroke
prevention in patients with CMB on MRI.
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